| Literature DB >> 26699510 |
Dong-ki Kim1, Hidetaka Nishida1, Su Yeon An1, Ashok K Shetty1, Thomas J Bartosh1, Darwin J Prockop2.
Abstract
Extracellular vesicles (EVs) secreted by cells present an attractive strategy for developing new therapies, but progress in the field is limited by several issues: The quality of the EVs varies with the type and physiological status of the producer cells; protocols used to isolate the EVs are difficult to scale up; and assays for efficacy are difficult to develop. In the present report, we have addressed these issues by using human mesenchymal stem/stromal cells (MSCs) that produce EVs when incubated in a protein-free medium, preselecting the preparations of MSCs with a biomarker for their potency in modulating inflammation, incubating the cells in a chemically defined protein-free medium that provided a stable environment, isolating the EVs with a scalable chromatographic procedure, and developing an in vivo assay for efficacy of the cells in suppressing neuroinflammation after traumatic brain injury (TBI) in mice. In addition, we demonstrate that i.v. infusion of the isolated EVs shortly after induction of TBI rescued pattern separation and spatial learning impairments 1 mo later.Entities:
Keywords: MSCs; efficacy assay; exosomes; neuroinflammation
Mesh:
Substances:
Year: 2015 PMID: 26699510 PMCID: PMC4711859 DOI: 10.1073/pnas.1522297113
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205